Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Eur J Surg Oncol ; 45(7): 1225-1231, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30879932

RESUMEN

AIM: To evaluate the pattern of tumor relapse of pathological complete response (pCR) patients with locally advanced rectal cancer (LARC) following neoadjuvant chemoradiotherapy (nCRT) and total mesorectal excision (TME), and to identify predictive factors of distant metastasis in pCR patients after nCRT. METHOD: This was a retrospective analysis of 118 LARC patients who achieved a pCR following nCRT and TME from 2008 to 2015. Clinicopathological and therapeutic parameters were evaluated as possible predictors of distant metastasis-free survival (DMFS), and COX regression analysis was performed. RESULTS: After a median follow-up of 57 months, the 5-year overall and disease-free survival rates were 94.7% and 88.1%, respectively. Overall, 6 patients (5.1%) died, no local recurrence occurred, 13 patients (11%) developed distant metastases, including lung (n = 5), liver (n = 2), bone (n = 3), lung and brain (n = 1), peritoneal (n = 1), and spleen (n = 1) metastasis. On univariate analysis, tumor distance from the anal verge (HR = 0.706, P = 0.039), acellular mucin pools (HR = 6.687, P = 0.002), and MUC1 expression (HR = 8.280, P < 0.001) were independently associated with DMFS. COX regression demonstrated that MUC1 expression (HR = 3.812, P = 0.041) remained to be an independent predictor of DMFS in pCR patients. CONCLUSION: Distant metastasis still remained a major concern in pCR patients following nCRT and TME. Tumor distance from the anal verge, acellular mucin pools, and MUC1 expression were associated with distant metastasis in patients with pCR. MUC1 staining remained to be an independent risk factor for DMFS. Such information could facilitate treatment decision in these patients, such as adjuvant chemotherapy and follow-up.


Asunto(s)
Adenocarcinoma/terapia , Neoplasias Óseas/epidemiología , Neoplasias Hepáticas/epidemiología , Neoplasias Pulmonares/epidemiología , Neoplasias del Recto/terapia , Adenocarcinoma/epidemiología , Adenocarcinoma/secundario , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/secundario , Neoplasias Encefálicas/epidemiología , Neoplasias Encefálicas/secundario , Capecitabina/administración & dosificación , Quimioradioterapia , Quimioterapia Adyuvante , Supervivencia sin Enfermedad , Femenino , Fluorouracilo/uso terapéutico , Humanos , Incidencia , Leucovorina/uso terapéutico , Neoplasias Hepáticas/secundario , Neoplasias Pulmonares/secundario , Masculino , Mesenterio/cirugía , Persona de Mediana Edad , Mucina-1/metabolismo , Mucinas/metabolismo , Terapia Neoadyuvante , Metástasis de la Neoplasia , Compuestos Organoplatinos/uso terapéutico , Oxaliplatino/administración & dosificación , Neoplasias Peritoneales/epidemiología , Neoplasias Peritoneales/secundario , Proctectomía , Modelos de Riesgos Proporcionales , Neoplasias del Recto/metabolismo , Neoplasias del Recto/patología , Inducción de Remisión , Estudios Retrospectivos , Neoplasias del Bazo/epidemiología , Neoplasias del Bazo/secundario
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA